Nabriva Therapeutics plc Comprehensive Income
Nabriva Therapeutics plc reported Comprehensive Income of -$82.76 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-03-12
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-12-31 was -$30.82M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-09-30 was -$52.83M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-06-30 was -$17.79M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-03-31 was -$13.34M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$82.76M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$114.78M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$74.34M.
- Nabriva Therapeutics plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$54.84M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$82.76M 10-K · filed 2020-03-12 | |||
| 2018-12-31 | -$30.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$83.65M derived: sum of 2 quarters · filed 2020-03-12 | -$101.44M derived: sum of 3 quarters · filed 2020-03-12 | -$114.78M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$52.83M 10-Q · filed 2018-11-06 | -$70.61M derived: sum of 2 quarters · filed 2018-11-06 | -$83.95M 10-Q · filed 2018-11-06 | -$106.24M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$17.79M 10-Q · filed 2018-08-09 | -$31.13M 10-Q · filed 2018-08-09 | -$53.42M derived: sum of 3 quarters · filed 2020-03-12 | -$75.62M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$13.34M 10-Q · filed 2018-05-08 | -$35.63M derived: sum of 2 quarters · filed 2020-03-12 | -$57.83M derived: sum of 3 quarters · filed 2020-03-12 | -$72.44M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$22.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$44.49M derived: sum of 2 quarters · filed 2020-03-12 | -$59.10M derived: sum of 3 quarters · filed 2020-03-12 | -$74.34M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$22.20M 10-Q · filed 2018-11-06 | -$36.81M derived: sum of 2 quarters · filed 2018-11-06 | -$52.05M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$14.61M 10-Q · filed 2018-08-09 | -$29.85M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$15.24M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$54.84M 10-K · filed 2019-03-12 | |||
| 2016-03-31 | -$13.56M 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | -$45.01M 10-K · filed 2018-03-16 | |||
| 2014-12-31 | -$10.85M 10-K · filed 2017-03-24 |